IndustryCompany release

LENZ Therapeutics Plans 50% Opex Cut as VIZZ Sales Reach $2.6m; CEO to Leave

🇺🇸 LENZ Therapeutics, Inc. (LENZ) · Wed 28 Oct 2026

The presbyopia eye-drop maker reported a 50% quarter-on-quarter sales rise, announced a Q4 reorganisation and filed VIZZ in three more markets, while its CEO steps down on 1 December.

LENZ Therapeutics reported net product sales of $2.6 million for VIZZ (aceclidine 1.44%), its presbyopia eye drop, in the third quarter of 2026. The company said this was an increase of about 50% on the second quarter.

Alongside the results, the company announced a reorganisation to be carried out in the fourth quarter. It is intended to reduce projected operating expenses for 2027 by more than 50%. The announcement was made on 28 October 2026, and the summary available does not detail which functions or activities will be affected.

LENZ also submitted marketing applications for VIZZ in Saudi Arabia (to the SFDA), Malaysia and Vietnam. These bring the number of ex-U.S. filings for the product to eleven. The summary does not give the status or expected timelines of the earlier submissions.

On the leadership side, chief executive Eef Schimmelpennink will step down. Chief financial officer Dan Chevallard will take over as interim CEO from 1 December 2026.

What it means for your team

  • Market-access teams should note that VIZZ's ex-U.S. footprint is widening, with eleven marketing applications now filed, including in the Gulf and South-East Asia.
  • A deep cost reduction and the CEO's departure may affect how the company resources regulatory and post-marketing activities, though no specifics have been disclosed.
  • Sales of $2.6 million in Q3 are still small in absolute terms, so uptake of the US launch remains a point to watch for competitors and payers.

Company's press release (SEC filing): LENZ Therapeutics, Inc. ↗

Article written by VigiEye from the official source (LENZ Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →